Overview

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of rabeprazole 10mg once and twice daily in maintenance therapy for PPI resistant gastroesophageal reflux disease patients.

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Rabeprazole